Orchard Therapeutics PLC
Lauren Richardson has a diverse work experience starting as a Summer Intern in 2010 at the Laboratory of Neuromodulation, Spaulding Rehabilitation Hospital. Lauren then worked as a Research Assistant at Colgate University before taking on a role as a Summer Intern at McLean-Franciscan Child/Adolescent Mental Health Unit. Lauren proceeded to work at Memorial Sloan-Kettering Cancer Center as an Infection Control Specialist and later as a Regulatory Compliance Coordinator. Lauren then joined C1 Consulting as a Senior Business Analyst. Lauren then transitioned to Charles River Associates, where they worked their way up from Consulting Associate to Associate Principal. Currently, Lauren is the Associate Director at Orchard Therapeutics and has recently been promoted to Director, Global Commercial Operations.
Lauren Richardson completed their Bachelor of Arts in Molecular Biology at Colgate University from 2008 to 2012. Lauren then pursued a Master's Degree in Health Policy & Management at Columbia University Mailman School of Public Health from 2013 to 2015. Before their college education, they attended Beverly High School in Beverly, MA from 2004 to 2008.
This person is not in any offices
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.